Trial Profile
A Non-Randomized, Open-Label, Multi-Center Phase 1/2 Study Evaluating the Safety, Pharmacokinetics and Efficacy of ABT-414 in Japanese Subjects With Malignant Glioma
Status:
Suspended
Phase of Trial:
Phase I/II
Latest Information Update: 29 Dec 2021
Price :
$35
*
At a glance
- Drugs Depatuxizumab mafodotin (Primary) ; Temozolomide
- Indications Glioma
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Acronyms INTELLANCE-J
- Sponsors AbbVie
- 01 Dec 2021 Results assessing safety, efficacy and pharmacokinetics of depatuxizumab mafodotin in japanese patients with malignant glioma, published in the Cancer Science.
- 21 Jul 2020 Planned End Date changed from 31 Dec 2020 to 27 Aug 2020.
- 21 Jul 2020 Planned primary completion date changed from 31 Dec 2020 to 27 Aug 2020.